Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs

Exelixis reports a sizable jump in Cometriq product sales, but it's more than offset by a huge jump in R&D and SG&A expenses.

May 1, 2014 at 7:25PM

A lot of hope is resting on Exelixis' (NASDAQ:EXEL) Cometriq as a possible treatment for metastatic castration-resistant prostate cancer; but tonight was all about the company's first-quarter earnings results.

For the quarter, the cancer-focused drug developer reported total revenue of $4.9 million consisting entirely of Cometriq product sales. Currently, Cometriq is only approved to treat metastatic medullary thyroid cancer. Comparably, revenue dipped by close to 50% from the prior-year period, but that was primarily due to the recognition of $7.8 million in licensing and contract revenue, which was missing in Q1 of this year. Cometriq sales totaled just $1.9 million in the year-ago period.

Research and development costs for the quarter soared 68%, to $54.8 million, as costs related to its clinical trials, as well as the need for personnel to run four phase 3 clinical studies, have increased. Exelixis notes the wind down of other studies partially offset this rise in R&D expenses.

Selling, general, and administrative costs rose by 40%, to $14.7 million, with an increase in personnel accounting for about half of the rise. The remainder of the increase related to marketing expenses for Cometriq, as well as stock-based compensation.

The end result of these higher costs was that net loss for the quarter ballooned 67%, to $74.6 million, or $0.39 per share, compared to a narrower loss of $0.24 per share in Q1 2013. Exelixis also announced that it ended the quarter with $407.7 million in cash and cash equivalents compared to $415.9 million in the sequential fourth quarter. Keep in mind its cash total includes proceeds from a 10 million share offering in January that raised approximately $75.6 million.

Sean Williams owns shares of Exelixis, but has no material interest in any other companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers